Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results

Shafak Aluwini; Peter Rooij; M Hoogeman; Wim Kirkels; Inger-karine Kolkman - Deurloo; C.H. Bangma

doi:10.1186/1748-717X-8-84

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results

Shafak Aluwini, Peter Rooij, M Hoogeman, Wim Kirkels, Inger-karine Kolkman - Deurloo, C.H. Bangma

Research output: Contribution to journal › Article › Academic › peer-review

71 Citations (Scopus)

6 Downloads (Pure)

Original language	Undefined/Unknown
Journal	Radiation Oncology
Volume	8
Issue number	84
DOIs	https://doi.org/10.1186/1748-717X-8-84
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/1748-717X-8-84

REPUB_74558_OA.pdfFinal published version, 351 KB

http://hdl.handle.net/1765/74558

Cite this

@article{648699f88d9344669f1c933da8f5e618,

title = "Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results",

author = "Shafak Aluwini and Peter Rooij and M Hoogeman and Wim Kirkels and {Kolkman - Deurloo}, Inger-karine and C.H. Bangma",

year = "2013",

doi = "10.1186/1748-717X-8-84",

language = "Undefined/Unknown",

volume = "8",

journal = "Radiation Oncology",

issn = "1748-717X",

publisher = "BioMed Central Ltd.",

number = "84",

}

TY - JOUR

T1 - Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results

AU - Aluwini, Shafak

AU - Rooij, Peter

AU - Hoogeman, M

AU - Kirkels, Wim

AU - Kolkman - Deurloo, Inger-karine

AU - Bangma, C.H.

PY - 2013

Y1 - 2013

U2 - 10.1186/1748-717X-8-84

DO - 10.1186/1748-717X-8-84

M3 - Article

SN - 1748-717X

VL - 8

JO - Radiation Oncology

JF - Radiation Oncology

IS - 84

ER -